Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Corvus Pharmaceuticals Q4 2025 Earnings Call - Soquelitinib posts strong AD efficacy, durability and funds to push multiple mid-stage trials
Corvus closed 2025 with a heavier R&D spend focused on soquelitinib, an oral selective ITK inhibitor, and fresh financing that materially extends its runway. Cohort 4 phase 1 atopic dermatitis data sh...
- Company reported Q4 2025 net loss of $12.3 million, essentially flat with Q4 2024 ($12.1 million).
- R&D spend jumped to $9.9 million in Q4 and $33.7 million for full-year 2025, driven mainly by clinical and manufacturing costs for soquelitinib and higher personnel expense.
- Cash and marketable securities were $56.8 million as of December 31, 2025; an upsized January offering generated net proceeds of $189 million, giving pro forma cash of ~ $246 million and a runway into Q2 2028, per management.
- +12 more takeaways
KORU Medical Systems Q4 2025 Earnings Call - CEO Exit and Succession as Company Guides to 2026 Profitability
KORU closed 2025 with clear momentum, reporting Q4 revenue of $10.9 million and full year revenue of $41.1 million, a 22% increase year over year. Management is pitching 2026 as the year to convert th...
- CEO transition announced, Linda Tharby to retire effective June 30, 2026, Adam Kalbermatten promoted to President March 15 and to become CEO July 1, providing planned leadership continuity.
- Q4 revenue $10.9 million, marking a third consecutive quarter of >20% revenue growth; full year 2025 revenue $41.1 million, up 22% year over year.
- Company initiated 2026 guidance of $47.5 million to $50 million in revenue, implying 15% to 22% growth, with targeted gross margins of 61% to 63%, positive adjusted EBITDA, and full year positive cash flow.
- +11 more takeaways
Mineralys Therapeutics Q4 2025 Earnings Call - FDA Accepts NDA for Lorundrostat, PDUFA Dec 22, 2026
Mineralys announced FDA acceptance of its NDA for lorundrostat with a PDUFA action date of December 22, 2026, moving the aldosterone synthase inhibitor from late-stage development toward a potential U...
- FDA accepted Mineralys Therapeutics NDA for lorundrostat, FDA set PDUFA target action date of December 22, 2026.
- NDA is supported by five clinical trials, notably pivotal Launch-HTN and Advance-HTN, plus Explore-CKD and the Transform-HTN open label extension.
- Lorundrostat delivered consistent, clinically meaningful blood pressure reductions and 24-hour control across trials, with a favorable safety profile.
- +15 more takeaways
GrabAGun Digital Holdings Q4 2025 Earnings Call - PEW Logistics launch signals shift from retailer to software-style platform
GrabAGun closed Q4 with clear top-line momentum and a strategic pivot. Q4 revenue was $29.6 million, up 14.1% year-over-year, driven by a 19.1% increase in firearm sales and 11.5% volume growth, outpe...
- Q4 net revenue of $29.6 million, up 14.1% year-over-year, was the company’s strongest quarter in 2025.
- Firearm sales were $25.7 million in Q4, up 19.1%, driven by 11.5% volume growth and favorable mix/pricing dynamics.
- Company outgrew the broader category while adjusted NICS background checks declined 4.1% in the same period, signaling market share gains rather than pure market tailwinds.
- +17 more takeaways
Nephros, Inc. Fourth Quarter 2025 Earnings Call - 33% Revenue Growth, Services and Education to Drive Recurring Revenue
Nephros closed 2025 with clear top-line momentum, reporting $18.8 million in revenue, up 33% year over year, and roughly $1.2 million in net income, its second consecutive profitable year. Active cust...
- Full-year 2025 revenue $18.8 million, up 33% versus 2024; Q4 2025 revenue $4.7 million, up 22% year over year.
- Net income for FY2025 approximately $1.2 million, marking the second consecutive year of profitability and the only two profitable years in company history.
- Active customer sites at year-end 2025 were 1,681, up from just over 1,500 at the end of 2024.
- +12 more takeaways
Inovio Pharmaceuticals Fourth Quarter 2025 Earnings Call - BLA for INO-3107 Accepted but FDA Flags Accelerated Approval Eligibility; Meeting Pending Ahead of Oct 30 PDUFA
Inovio’s headline is clear and precarious. The FDA has accepted the company’s BLA for INO-3107 in recurrent respiratory papillomatosis for review under the Accelerated Approval Program, with a PDUFA t...
- FDA accepted Inovio's BLA for INO-3107 under the Accelerated Approval Program with a standard 10-month review and a PDUFA target date of October 30, 2026.
- During the 60-day filing review the FDA flagged a preliminary conclusion that Inovio had not provided adequate information to justify Accelerated Approval eligibility, creating a material open issue.
- Inovio submitted an assessment aid and an sBLA in February to expand its rationale for accelerated approval and is awaiting a scheduled meeting with the FDA to resolve eligibility questions; meanwhile the BLA remains under active review.
- +15 more takeaways
Vaxart Q4 2025 Earnings Call - Dynavax Pact Validates Platform, Sentinel Cohort Safety Readout Early Q2 2026
Vaxart used the quarter to cement a high-profile tie-up for its oral COVID-19 pill and to publish encouraging early norovirus biology, while reminding investors the company still runs on a finite runw...
- Dynavax collaboration signed Nov 2025 produced $25 million upfront and a $5 million equity investment, considered validation of Vaxart’s oral platform.
- Sanofi completed its acquisition of Dynavax on Feb 10, 2026, and Vaxart reports productive interactions with Dynavax now operating as a Sanofi company.
- Under the Dynavax deal Vaxart can receive an additional $50 million if Dynavax elects to continue after submission of Phase 2B data to the FDA, plus up to approximately $195 million in regulatory milestones, $425 million in sales milestones, and tiered royalties in the low to mid-teens, totaling potential value near $700 million.
- +12 more takeaways
Funko Q4 2025 Earnings Call - Momentum Into 2026: Better-than-expected Q4, guidance for flat to +3% sales and $70-80M adjusted EBITDA
Funko closed Q4 2025 with stronger-than-expected results and margin momentum, reporting $273 million in net sales, 41% gross margin, and $23 million of adjusted EBITDA. Management points to faster pro...
- Q4 net sales were $273 million, up 9% sequentially and above company expectations.
- Gross margin for Q4 was 41%, and Funko has been above 40% in seven of the last eight quarters.
- Q4 adjusted EBITDA was $23 million, at the high end of guidance; SG&A was $91 million, down 12% year-over-year.
- +13 more takeaways
Quest Resource Holding Corporation Q4 2025 Earnings Call - Industrial Volume Drop Masks Operational Gains, Cash and Debt Moves Buy Time
Quest reported a pronounced slowdown in Q4 as industrial volumes and a prior mall divestiture drove revenue to $58.9 million, down 16% year-over-year and 7% sequentially. Management stressed that volu...
- Revenue of $58.9 million in Q4, down 16% year-over-year and 7% sequentially, driven primarily by weaker industrial volumes and a divested mall-related business.
- Industrial and mall divestiture together reduced quarterly revenue by $10.7 million versus last year; excluding those headwinds, the rest of the business grew modestly by $7.4 million, or about 5% year-over-year.
- Gross profit was $9.1 million in Q4, down 15% year-over-year and 21% sequentially, producing a gross margin of 15.5%.
- +12 more takeaways
Karat Packaging Q4 2025 Earnings Call - Paper bag ramp and tariff tailwinds set stage for low double-digit growth
Karat Packaging closed Q4 2025 with a clear growth story under pressure. Net sales rose 13.7% to $115.6 million on double-digit volume across major markets and pricing that turned positive for the fir...
- Net sales grew 13.7% year over year in Q4 2025 to $115.6 million, driven by strong double-digit volume growth across all major markets and pricing that turned positive for the first time since early 2023.
- Gross margin fell to 34.0% in Q4 2025 from 39.2% a year earlier, primarily due to a $8.4 million increase in duty and tariff costs and higher import-related expenses; import costs rose to 14.5% of sales from 8.3% in the prior-year quarter.
- Management expects tariff relief and a stabilized USD/NTD exchange rate to begin providing margin tailwinds starting in Q2 2026, and they forecast full-year 2026 gross margin and adjusted EBITDA margin to improve year over year under the current tariff environment.
- +12 more takeaways